And litigation…

FDA acknowledges GBS, intracranial thrombosis, peer-reviewed describes: transverse myelitis, stroke, neuropathy, tinnitus, hearing loss, headaches, related risks HTNive crisis, cardiomyopathy, and SCD . Disability risks demand free choice on this class of medical products. pic.twitter.com/zxqttLSNt8

— Peter A. McCullough, MD, MPH® (@P_McCulloughMD) May 11, 2022